April 2017

New Product - Briviact

Briviact (brivaracetam) displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain. Binding to SV2A is considered to be the primary mechanism for brivaracetam anticonvulsant activity, however, the precise mechanism by which brivaracetam exerts it’s anticonvulsant activity has not been fully elucidated. Briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with epilepsy. Briviact is available as 25 mg and 50 mg tablets in packs of 56’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au